Pfizer Inc announced today that the Phase 3 INTORSECT ( B1771003 ) study, evaluating TORISEL ( temsirolimus ) in patients with advanced renal cell carcinoma ( RCC ) whose disease had progressed on or after SUTENT ( sunitinib malate ) therapy, did not meet the primary endpoint of prolonging progression free survival ( PFS ) when compared to sorafenib .

Pfizer Inc. announced that it has stopped a Phase 3 clinical trial of Lyrica ( pregabalin ) in patients with neuropathic pain associated with HIV neuropathy, a form of nerve damage characterized by burning pain usually beginning in the feet.

Pfizer Inc. announced that a Phase 3 randomized withdrawal design study for Lyrica ( pregabalin ) in patients with inadequately treated painful diabetic peripheral neuropathy ( pDPN ) did not meet its primary efficacy endpoint.

Roche announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy of the subcutaneous (SC) formulation of RoACTEMRA ( tocilizumab , known as ACTEMRA outside Europe) 162 mg weekly compared to 8 mg/kg RoACTEMRA intravenous (IV) formulation every 4 weeks.

Merck announced final results from a Phase III, open-label study designed to compare the impact of two anemia management strategies on sustained virologic response ( SVR ) in patients with chronic hepatitis C virus ( HCV ) genotype 1 infection treated with VICTRELIS  ( boceprevir ) in combination with PEGINTRON  ( peginterferon alfa-2b ) and ribavirin (P/R).

Abbott announced it has acquired an exclusive license for several novel biomarkers from Stanford University for use in developing a molecular diagnostic test that could satisfy a longstanding unmet medical need: differentiating aggressive from nonaggressive prostate cancer.

Abbott announced the results from a Phase 3 trial evaluating the company's investigational compound for advanced Parkinson's disease, levodopa-carbidopa intestinal gel ( LCIG ).

Novo Nordisk announced that the US Food and Drug Administration FDA) has approved to update the product label for Victoza ( liraglutide [ rDNA ] injection). Research data shows superior blood sugar control and weight reduction.

GlaxoSmithKline announced that topline results have been received from seven of the eight Harmony Phase III studies investigating the use of albiglutide in type 2 diabetes. Albiglutide is an investigational once weekly glucagon-like peptide-1 ( GLP-1 ) agonist.

Sanofi and Regeneron Pharmaceuticals, Inc. announced that data from two Phase 2 trials with  SAR236553 / REGN727 , an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 ( proprotein convertasesubtilisin / kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.